Gleicher Norbert, Elkayam Uri
Center for Human Reproduction and the Foundation for Reproductive Medicine, New York, NY, USA.
Autoimmun Rev. 2009 Mar;8(5):384-7. doi: 10.1016/j.autrev.2008.12.003. Epub 2008 Dec 16.
The timing of peripartum cardiomyopathy (PPCM) in association with pregnancy is typical of autoimmune conditions. This review addresses this fact by presenting PPCM as an organ specific autoimmune response (though not necessarily as an outright autoimmune condition), akin to autoimmune responses seen with complications of allogeneic organ transplantations. Since pregnancy represents a semi-allograft (representing paternal alloantigens), pregnancy and allogeneic organ transplants can be expected to be subject to similar allograft tolerance mechanisms, and also to share potential complications of normal allograft tolerance. This review suggests that PPCM represents a cardio-toxic autoimmune component within a more general immunological malfunction of tolerance of the fetal allograft by the maternal immune system. Treatment of PPCM with therapies, proven successful in graft versus host disease and organ rejection, may, therefore, be successful. Their success would also be confirmatory of such a concept.
围产期心肌病(PPCM)与妊娠相关的发病时间是自身免疫性疾病的典型特征。本综述通过将PPCM呈现为一种器官特异性自身免疫反应(尽管不一定是直接的自身免疫性疾病)来阐述这一事实,这类似于同种异体器官移植并发症中所见的自身免疫反应。由于妊娠代表一种半同种异体移植(代表父系同种异体抗原),因此可以预期妊娠和同种异体器官移植会受到相似的同种异体移植耐受机制影响,并且也会有正常同种异体移植耐受的潜在并发症。本综述表明,PPCM代表了母体免疫系统对胎儿同种异体移植耐受的更普遍免疫功能紊乱中的一种心脏毒性自身免疫成分。因此,用在移植物抗宿主病和器官排斥反应中已被证明成功的疗法治疗PPCM可能会取得成功。它们的成功也将证实这一概念。